v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 6,561,840 $ 4,823,745
Advances on research and development contract services 147,017 150,241
Prepaid insurance 86,654 109,029
Other prepaid expenses and current assets 23,957 10,249
Total current assets 6,819,468 5,093,264
Total assets 6,819,468 5,093,264
Current liabilities:    
Accounts payable and accrued expenses, including $54,972 and $32,500 to related parties at September 30, 2022 and December 31, 2021, respectively 307,398 225,965
Research and development contract liabilities 100,930 76,961
Total current liabilities 408,328 302,926
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 16,646,593 shares at September 30, 2022 and 13,746,593 shares at December 31, 2021 1,664 1,374
Additional paid-in capital 44,672,871 38,371,128
Accumulated deficit (41,763,395) (37,082,164)
Total stockholders’ equity 6,411,140 4,790,338
Total liabilities and stockholders’ equity $ 6,819,468 $ 5,093,264

Source